Prostate disorder

This phase 3 trial tests whether a shorter course of higher-dose radiation can match or improve upon standard pelvic radiation plus a brachytherapy boost for men with high-risk prostate cancer. Participants also receive hormone therapy for 28 months. The study compares side effec…

This early-phase study tests a personalized vaccine made from a patient's own immune cells and tumor markers. It aims to help the immune system attack advanced prostate cancer that has stopped responding to standard treatments. About 9 to 18 men will receive four doses over eight…

This early-stage study tests a personalized vaccine (PGV001) combined with an immune booster (CDX-301) in 27 men who have had aggressive prostate cancer but currently show no signs of tumor. The goal is to see if the vaccine is safe and can train the immune system to recognize an…

This Phase 3 trial tests whether adding talazoparib (a targeted drug) to standard hormone therapy (enzalutamide) works better than hormone therapy alone for men with metastatic prostate cancer that has a specific DNA repair mutation. About 600 men are participating. The study mea…

This phase 3 trial tests whether treatment for high-risk prostate cancer can be personalized based on a patient's genetic risk score. For those with a low genetic risk, a shorter course of hormone therapy plus radiation may be as effective as the standard 24-month treatment, with…

This study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …

This phase III trial uses a genetic test (Decipher score) to personalize treatment for men with unfavorable intermediate-risk prostate cancer. For those with a high genetic risk, the study tests adding darolutamide to standard hormone therapy and radiation. For those with low gen…

This Phase 3 trial tests whether adding talazoparib to enzalutamide can slow the spread of metastatic castration-resistant prostate cancer (mCRPC). About 1,054 men with this advanced cancer are taking either the drug combo or a placebo plus enzalutamide. The study tracks how long…

This phase III trial tests whether adding the drug apalutamide to standard hormone therapy and radiation helps men with prostate cancer that has spread to nearby lymph nodes after surgery. About 586 participants will receive either the usual treatment or the usual treatment plus …

This trial asks whether removing lymph nodes during prostate cancer surgery lowers the chance of the cancer returning. Men with clear scans before surgery are randomly assigned to have lymph nodes removed or not. The study also tests other surgical tweaks, like how the incision i…

This phase II trial tests whether adding the hormone-blocking drug relugolix to standard radiation therapy can slow cancer growth in men with prostate cancer that has spread to a few other spots in the body (oligometastatic). About 194 participants will receive either radiation a…

This study tests whether robot-assisted removal of the prostate, along with lymph node dissection, can help control cancer in men with oligometastatic hormone-sensitive prostate cancer—cancer that has spread to a few spots in the spine or pelvis. Participants have been on hormone…

This trial is testing an experimental oral drug called ODM-208 in men with metastatic castration-resistant prostate cancer, a type of prostate cancer that has spread and no longer responds to standard hormone therapy. The main goal is to find the highest safe dose and to assess t…

This trial tests whether proton therapy, a more precise form of radiation, causes fewer long-term bowel side effects than standard photon therapy in men with high-risk prostate cancer. Participants receive the same radiation dose and schedule, but one group gets protons and the o…

This pilot study is testing a device that uses ultrasound images to guide a laser or freezing probe directly into prostate tumors. The goal is to destroy only the cancerous tissue while sparing healthy areas. Thirty men with low- to intermediate-risk prostate cancer that hasn't s…

This study tests a new drug, APL-5125, in adults with advanced solid tumors like colorectal, pancreatic, and ovarian cancer. The goal is to see if the drug is safe and can shrink or control tumors. About 100 participants will receive the drug in two phases to find the best dose a…

This study tests whether a higher dose of proton radiation, focused on tumors seen on MRI, can better control high-risk prostate cancer. About 100 participants will receive radiation over 8-9 weeks, plus hormone therapy for 18 months. The goal is to lower the chance of cancer ret…

This phase 3 trial is testing whether a new type of targeted radiation therapy, called 177Lu-PSMA-I&T, can slow the progression of metastatic castration-resistant prostate cancer better than standard hormone therapy. The study enrolls men with prostate cancer that has spread and …

This study tests a gel called SpaceIT that is placed between the prostate and rectum before radiation therapy for prostate cancer. The gel acts as a spacer to reduce radiation reaching the rectum, potentially lowering side effects. About 230 adults with low- to intermediate-risk …

This trial is testing whether adding an immunotherapy drug called ipilimumab to the standard hormone therapy of abiraterone plus prednisone can help men with advanced prostate cancer that has spread and no longer responds to hormone treatment. The study includes men aged 18 and o…

This study looks at the long-term safety of the drug enzalutamide in people with prostate cancer who have already been taking it in a previous study and are still benefiting. About 900 participants will continue their current treatment and be monitored for side effects. The goal …

This phase 2 study tests a combination of hormone therapy, chemotherapy, and an immunotherapy drug (nivolumab) in men with metastatic hormone-sensitive prostate cancer that has spread widely. The goal is to see if this triple approach can lower PSA levels more effectively. The tr…

This study compares a minimally invasive water vapor treatment (REZŪM) to taking two drugs together for men with an enlarged prostate that didn't get better with one drug. It includes 155 sexually active men aged 45 and older. The goal is to see which approach better improves uri…

This study is tracking 238 adults who are already scheduled to have a procedure for kidney stones or an enlarged prostate (BPH) using Boston Scientific devices. The main goal is to see how often serious side effects happen with these tools in real-world use. Researchers will also…

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This Phase 3 trial tests whether adding the experimental drug mevrometostat to standard enzalutamide can slow cancer growth better than current treatments in men with metastatic castration-resistant prostate cancer that has progressed after abiraterone. About 600 participants wil…

This study tests whether adding abiraterone and prednisone to standard hormone therapy works better than hormone therapy alone for men whose prostate cancer has come back after surgery or radiation. About 310 men will receive either hormone therapy or hormone therapy plus abirate…

This phase 2 trial tests whether giving hormone therapy before prostate surgery helps men with high-risk prostate cancer recover erectile function better. About 90 men will receive either apalutamide alone or a combination of apalutamide, abiraterone, GnRH agonist, and prednisone…

This early-phase trial is testing a new treatment called TmPSMA-02 for men with metastatic castrate-resistant prostate cancer that has progressed after standard therapies. The treatment uses the patient's own immune cells (T cells) that are genetically modified to recognize and a…

This phase 2 trial tests whether white button mushroom extract can lower PSA levels in men with prostate cancer that has returned after treatment or is low-risk and not yet treated. About 133 men will take the supplement or be observed. The goal is to see if the mushroom affects …

This study tests whether adding the drug abemaciclib to standard treatment (abiraterone acetate plus prednisone) can help men with metastatic castration-resistant prostate cancer live longer without their cancer getting worse. About 393 participants will receive either the combin…

This phase 3 trial tests a radioactive drug called 177Lu-PSMA-617 in 469 men with advanced prostate cancer that has stopped responding to hormone therapy. The drug seeks out and delivers radiation directly to cancer cells. Researchers compare it to switching to another hormone th…

This trial tests whether two different PET/CT tracers—fluciclovine F18 and 68Ga-PSMA—can better guide radiation therapy planning for men with prostate cancer who have a rising PSA after surgery. The goal is to see if one tracer more accurately spots remaining cancer cells, allowi…

This trial tests whether a focal treatment called irreversible electroporation (IRE) can control localized prostate cancer as effectively as radical treatments, but with fewer side effects. IRE uses high-voltage electrical pulses to destroy tumor cells while sparing surrounding h…

This early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…

This early-stage study tests a treatment called bipolar androgen therapy for men with advanced prostate cancer that no longer responds to standard hormone therapy. The treatment involves raising and lowering testosterone levels in a controlled way to try to slow cancer growth. Th…

This phase 2 trial tests whether adding the chemotherapy cabazitaxel to standard hormone therapy (abiraterone) can better control advanced prostate cancer that has spread and stopped responding to initial treatment. The study involves 223 men whose cancer progressed after docetax…

This study follows over 800 men with non-metastatic castration-resistant prostate cancer who are already taking darolutamide as part of their normal care. Researchers are tracking side effects and how well the drug controls the cancer in real-world conditions, outside of a strict…

This phase 3 trial is testing whether giving the chemotherapy drug docetaxel more often but at a lower dose—every 2 weeks instead of every 3 weeks—can reduce severe side effects in men with metastatic hormone-sensitive prostate cancer. All participants also receive the standard c…

This study explores whether regular aerobic exercise, specifically walking about 300 minutes per week, can change certain biomarkers in the blood that are linked to cancer risk. Participants are adults who have completed all cancer therapy and have either clonal hematopoiesis (a …

This phase 3 trial tests whether focused high-intensity ultrasound (HIFU) can destroy low-risk prostate tumors without the side effects of radical treatments. Men aged 50-80 with a single, low-risk tumor will be randomly assigned to either HIFU or active surveillance (regular mon…

This study tests a procedure called TULSA that uses MRI images to guide high-energy ultrasound waves to destroy prostate cancer tumors. About 21 adults with early-stage prostate cancer that shows up on MRI will receive this heat-based treatment. The goal is to see if the approach…

This study is testing an experimental drug called ACE-86225106 in adults with advanced solid tumors that are difficult to treat or have stopped responding to standard therapies. The drug works by blocking a protein that helps cancer cells repair themselves, potentially slowing or…

This study tests a new drug combination (FPI-2265 and olaparib) in 85 men with advanced prostate cancer that no longer responds to standard hormone therapy. The goal is to see if the treatment can shrink tumors or lower PSA levels by at least 50%. Participants must have tried at …

This trial compares two ways of delivering radiation to the pelvis in men with unfavorable intermediate- or high-risk prostate cancer. One group receives the standard 25 sessions of radiation, while the other receives just 5 sessions with a higher dose per session. The goal is to…

This trial compares two surgical procedures for men with an enlarged prostate causing urinary obstruction: low power HOLEP, which uses a laser, and TURP, a traditional cutting technique. The goal is to see which approach better relieves lower urinary tract symptoms, measured by c…

This study tested a drug called apalutamide in over 1,200 men with a type of prostate cancer that has stopped responding to hormone therapy but has not yet spread. The goal was to see if the drug could delay the cancer from spreading to bones or other organs. Participants took ei…

This phase 2 trial tests whether adding cediranib to olaparib works better than olaparib alone for men with metastatic castration-resistant prostate cancer. Olaparib blocks DNA repair in cancer cells, while cediranib stops tumor blood vessel growth. The study involves 90 particip…

This trial asks whether giving a higher dose of radiation (80 Gy) is better than the standard dose (70 Gy) for men with aggressive prostate cancer who are also receiving hormone therapy. The study includes about 500 men with unfavorable prostate cancer features, such as advanced …

This phase 2 trial tests whether adding enzalutamide to standard hormone therapy and chemotherapy can better control metastatic prostate cancer that still responds to hormones. About 40 men with advanced disease will receive all three drugs. The main goal is to see how many achie…

This study tests a new approach for men with intermediate-risk prostate cancer. First, doctors use electric pulses (IRE) to destroy tumor cells, followed by precise radiation (MRgRT). The goal is to see if this combination is safe and can keep cancer away for at least a year. Abo…

This trial investigates whether real-time motion management techniques—like triggered imaging and MLC tracking—can safely reduce the target margins used during radiotherapy for prostate and lung cancer. By adjusting the radiation beam to follow tumor movement, researchers aim to …

This early-stage trial tests a new drug called PSW-1025, which delivers a radioactive particle (astatine-211) directly to prostate cancer cells. The goal is to see if this targeted approach is safe and tolerable for men with castration-resistant prostate cancer, a form that no lo…

This early-stage trial is testing a new drug called IPH4502 in people with advanced solid tumors that have a specific protein called Nectin-4. The main goals are to check the drug's safety and find the best dose. About 145 participants will receive the drug, and researchers will …

This early-stage trial tests whether combining two antibodies (anti-IGF-1R and anti-PD-1) can safely control metastatic castration-resistant prostate cancer (mCRPC) — a type that has stopped responding to hormone therapy. Seven men with advanced disease will receive the combinati…

This early-phase trial tests whether a patient's own immune cells, modified to target a protein called PSMA on prostate cancer cells, are safe and can shrink tumors or lower PSA levels. It involves 7 to 18 men with metastatic castration-resistant prostate cancer that has stopped …

This study observes how abiraterone acetate tablets work in real-world settings for Chinese men with metastatic prostate cancer. Researchers will track safety, side effects, and effectiveness, including PSA levels and survival. The goal is to understand how well the drug performs…

This phase 2 trial is testing whether combining three drugs—ZEN-3694, enzalutamide, and pembrolizumab—can shrink tumors or lower PSA levels in men with metastatic castration-resistant prostate cancer that has worsened despite prior treatment. ZEN-3694 blocks a protein that fuels …

This study tests whether combining two immunotherapy drugs, nivolumab and ipilimumab, can shrink tumors in people with rare cancers of the urinary or reproductive systems. About 100 adults with advanced disease that cannot be removed by surgery are taking part. The main goal is t…

This early-phase trial tests a new type of immune cell therapy (PSMA-UCAR T cells) in 3 men with advanced prostate cancer that no longer responds to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants must have me…

This early-stage study tests an oral drug called LY3410738 in people with advanced solid tumors (like bile duct cancer, cartilage cancer, or brain tumors) that have specific IDH1 or IDH2 mutations. The main goal is to find a safe dose and see if the drug can shrink tumors. About …

This trial tests two types of radiation therapy—proton therapy and IMRT—for men with low- to intermediate-risk prostate cancer. The goal is to see if a shorter, more intense radiation schedule (hypofractionation) can improve cancer control while reducing side effects. The study t…

This phase II trial tests a highly precise, short-course radiation therapy (SBRT) combined with hormone therapy for men whose PSA levels rise after prostate cancer surgery. The goal is to control the cancer while reducing side effects by delivering higher radiation doses in fewer…

This study tests whether different combinations of diet and exercise support tools—like educational materials, text messaging, and coaching—can improve outcomes for men with prostate cancer who choose surgery. Researchers will track PSA recurrence and quality of life over time. T…

This phase 2 trial tests whether adding apalutamide, abiraterone, and prednisone after chemotherapy can better control metastatic prostate cancer that still responds to hormone therapy. Seven men with high-risk, untreated disease are receiving this combination. The main goal is t…

This study tests whether a precise type of radiation (SBRT) alone can control unfavorable intermediate-risk prostate cancer, avoiding the need for hormone therapy. About 215 participants will receive SBRT, with the radiation dose guided by a genetic test (Decipher) to personalize…

This trial tests whether placing a dehydrated human amnion chorion membrane (dHACM) over the nerves during robot-assisted prostate removal helps men recover erectile function and urinary control sooner. The study enrolls men aged 40 to 80 with localized prostate cancer who have g…

This study investigates whether adding a non-invasive magnetic stimulation treatment to standard pelvic floor exercises helps men recover bladder control more quickly after prostate surgery for an enlarged prostate. Participants who experience urine leakage after surgery will be …

This phase 2 study tests a combination of radiation, hormone therapy (ADT), and two drugs (abiraterone and olaparib) in 21 men with prostate cancer that has spread to a few spots in the body. The goal is to see if this approach can prevent the cancer from growing or spreading fur…

This study looks at whether a special program called Primary Care Connect (PC2) helps cancer survivors who also have conditions like high blood pressure, diabetes, or high cholesterol keep their heart risks under control during cancer treatment. About 266 adults with early-stage …

This phase 2 trial is testing whether giving the targeted drug olaparib (Lynparza) along with hormone therapy for 6 months before surgery can shrink or eliminate prostate cancer in men with high-risk disease and specific gene mutations. About 32 men will receive the treatment, th…

This study tests whether a precise, high-dose radiation boost using CyberKnife can improve outcomes for men with high-risk prostate cancer that has not spread. Participants receive standard hormone therapy and radiation to the prostate and nearby lymph nodes, followed by a CyberK…

This phase 3 trial tested enzalutamide (Xtandi) plus leuprolide in over 1,000 men with high-risk prostate cancer that had not spread but was progressing after initial treatment. The goal was to see if the combination could delay the cancer from spreading to other parts of the bod…

This trial tests a device called the ProVee expander, which is placed in the prostate to relieve urinary blockage caused by an enlarged prostate (BPH). It involves about 40 men over 45 who have moderate to severe symptoms and have not found relief from medication. The study check…

This phase 2 trial is testing a combination of two drugs—cabozantinib (a pill) and nivolumab (an infusion)—in 47 men with metastatic castration-resistant prostate cancer, a type that has stopped responding to hormone therapy. The main goal is to see if the treatment can delay can…

This study tests whether a shorter, more intense radiation treatment (5 sessions) is better than the standard 20-session approach for men with intermediate- or high-risk prostate cancer that hasn't spread. The goal is to improve cancer control while keeping side effects low. Abou…

This study compares standard fluid management to a newer method using the Plethysmography Variability Index (PVI) during prostate surgery for enlarged prostate. The goal is to see if PVI-guided care reduces risks like fluid overload or low blood pressure. Fifty-eight men aged 50-…

This observational study follows about 1,600 men with metastatic hormone-sensitive prostate cancer who are taking darolutamide plus hormone therapy, with or without chemotherapy. Researchers will track how many men have undetectable PSA levels after one year, as well as overall s…

This early-stage trial tests whether a patient's own immune cells can be genetically modified to recognize and attack prostate cancer cells. Thirteen men with advanced prostate cancer that no longer responds to hormone therapy will receive infusions of their own engineered T cell…

This phase 2 trial tests the drug bortezomib in 22 men with metastatic castration-resistant prostate cancer that has a specific genetic change (PTEN deletion). The main goal is to see if bortezomib can lower PSA levels by at least 30%. Participants receive bortezomib injections f…

This study looks at how prostate cancer treatments, especially hormone therapy, affect heart health. It includes two parts: one that follows men over time to track heart problems, and another that tests whether a program of healthy eating, exercise, smoking cessation, and medicat…

This study tests a precise radiation technique called adaptive SBRT for men with high-risk or unfavorable intermediate-risk prostate cancer. The treatment targets the prostate and pelvic lymph nodes while giving an extra radiation boost to tumor spots seen on MRI. The goal is to …

This phase 3 trial tests whether adding the targeted drug abemaciclib to standard hormone therapy (abiraterone plus prednisone) can delay cancer growth in men with high-risk prostate cancer that has spread to bones or organs. Participants receive either abemaciclib or a placebo a…

This trial tests whether giving a lower dose of radiation in just two sessions can reduce urinary side effects for men with intermediate-risk prostate cancer. All participants receive radiation on an MR-Linac, a machine that combines MRI imaging with radiotherapy for precise targ…

This study compares two types of radiation therapy for men with favorable or low-tier intermediate risk prostate cancer: low dose rate (LDR) brachytherapy, which uses permanent radioactive seeds, and high dose rate (HDR) brachytherapy, which uses temporary radioactive material. T…

This study looks at whether adding a precise type of radiation (SBRT) to intermittent hormone therapy can better control prostate cancer that has spread to a few places in the body. The trial involves 60 men whose cancer was detected by a special PET scan but not by standard scan…

This trial tests a minimally invasive treatment that uses microwaves to destroy only the cancerous part of the prostate, leaving healthy tissue intact. The goal is to control the cancer while avoiding common side effects of full prostate removal, such as urine leakage and erectil…

This phase 2 trial tests whether adding a second DNA vaccine to a standard immunotherapy (pembrolizumab) can improve outcomes for men with castration-resistant metastatic prostate cancer. About 60 participants will receive either one or two DNA vaccines along with pembrolizumab f…

This study is for men whose prostate cancer has returned in the same area after they already had radiation and surgery. The researchers want to see if giving a very precise, high-dose radiation treatment (called SBRT) along with the diabetes drug metformin can safely control the …

This study tests a biodegradable balloon, called a rectal spacer, placed between the prostate and rectum before radiation therapy for prostate cancer. The goal is to see if it safely reduces radiation exposure to the rectum, potentially lowering side effects. Up to 150 men with l…

This study is testing whether giving high-dose radiation only to the tumor area (focal HDR brachytherapy) can control early-stage prostate cancer while causing fewer side effects than treating the whole gland. Sixty men with low- or favorable intermediate-risk prostate cancer wil…

This was a planned early-stage trial to test a new oral drug called ERW316, alone or with hormone therapies, in people with advanced breast cancer or other solid tumors. The study aimed to find a safe dose and check for side effects. However, the trial was withdrawn before any pa…

This phase 2 trial investigates whether adding a targeted radiation therapy called Lu-PSMA to the standard hormone drug enzalutamide can delay cancer progression in men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy. Participants r…

This study tests whether adding olaparib to standard abiraterone therapy can slow the growth of metastatic castration-resistant prostate cancer better than abiraterone alone. About 110 men who have not had chemotherapy or newer hormone drugs for this stage of cancer will particip…

This study looks at whether a whole-food, plant-based diet can help overweight or obese men with prostate cancer who are on hormone therapy (ADT) control their weight and reduce inflammation. About 76 men will either receive free plant-based meals at home or standard nutrition ad…

This study tests a device called Vanquish that uses water vapor (steam) to destroy prostate cancer tissue in men with intermediate-risk, localized prostate cancer. The goal is to control the cancer while avoiding common side effects like incontinence and impotence. About 400 men …

This phase II trial is testing a shorter course of proton beam radiation (hypofractionated) in 241 men with early-stage prostate cancer that hasn't spread. The goal is to see if this precise radiation can kill cancer cells while causing fewer bowel and bladder side effects compar…

This phase 2 trial is testing whether adding the drug sunitinib to standard hormone therapy can shrink or control high-risk prostate cancer before the prostate is removed. About 64 men with localized but aggressive prostate cancer will receive sunitinib pills plus a hormone block…

This phase 2 trial tests a multi-drug approach for men with aggressive variant prostate cancer that has spread. First, patients receive chemotherapy (cabazitaxel and carboplatin) plus an immunotherapy (cetrelimab). Then, they are randomly assigned to take either a PARP inhibitor …

This study compares two surgical methods for treating benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate. The trial involves 140 men aged 50-80 with prostates of 80 mL or larger who are candidates for holmium laser enucleation. One group receives the …

This phase 2 trial tests whether giving a combination of enteric-coated aspirin, rintatolimod, and interferon-alpha 2b before prostate cancer surgery can boost the immune system's attack on tumors. The study involves 12 men with localized prostate cancer who are scheduled for sur…

This phase II trial tests two types of radiation therapy (proton beam or IMRT) given in fewer, larger doses for men whose prostate cancer has returned or spread to a few spots after initial treatment. The main goal is to see if this shorter course causes fewer serious side effect…

This phase II trial is testing a combination of two drugs—sEphB4-HSA and pembrolizumab (Keytruda)—in 70 people with advanced bladder or prostate cancers that have not responded to standard treatments. The goal is to see if the combo is safe and can shrink tumors. Participants rec…

This early-phase study tests a new oral drug called E7386 in about 60 adults with advanced solid tumors (like desmoid tumors) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also watch for any tu…

This study tests whether using highly focused radiation (SBRT) on a limited number of growing cancer spots can help control the disease in patients with metastatic breast or genito-urinary cancers. Instead of switching to a new drug when some tumors start growing, doctors will ta…

This phase 2 trial is testing a drug called sacituzumab govitecan in 31 men with metastatic castration-resistant prostate cancer that has worsened despite hormone therapy. The drug works like a smart bomb, delivering chemotherapy directly to cancer cells. Researchers are measurin…

This early-phase trial tests a new type of immunotherapy for men with advanced prostate cancer that no longer responds to hormone therapy. The treatment uses the patient's own immune cells, which are genetically modified in a lab to recognize and attack cancer cells that carry a …

This phase 2 trial tests a DNA vaccine (pTVG-HP) plus the immunotherapy drug nivolumab in 19 men whose prostate cancer has returned after surgery but has not spread. The goal is to see if the combination can safely lower PSA levels to undetectable and delay cancer spread. Partici…

This study follows 60 men with an enlarged prostate who already used the Butterfly device for a year. Researchers will track safety and symptom relief for up to 5 years. The goal is to see if the device remains effective and safe over the long term.

This phase 2 trial studies whether adding radium-223 to enzalutamide works better than enzalutamide alone in men with castration-resistant prostate cancer that has spread to bones. Enzalutamide blocks male hormones that fuel cancer growth, while radium-223 delivers targeted radia…

This study tests four different tools—coaching, education, text messages, and health coaching—to help cancer survivors improve their diet, physical activity, and weight. About 350 adults who have completed treatment for several cancer types will use these tools for up to 48 weeks…

This early-phase study tests two drugs together—nivolumab (Opdivo) and Radium-223 (Xofigo)—in 39 men with metastatic castration-resistant prostate cancer that has spread to the bones. The main goals are to check safety and see if the combination can reduce tumor DNA in the blood.…

This phase II trial tests whether adding precise radiation (SBRT) to the hormone therapy darolutamide can delay cancer progression in men with castration-resistant prostate cancer that has only a few new spots of growth. The study involves 66 participants and measures how long it…

This early-phase trial is testing whether giving an extra dose of the immunotherapy drug Sipuleucel-T can strengthen the immune system's attack on prostate cancer that has spread and stopped responding to hormone therapy. Fifteen men with this advanced cancer will receive three i…

This phase 2 trial tests whether giving a radioactive drug (177Lu-PSMA) before precise radiation (SBRT) can better control prostate cancer that has come back in 1 to 5 spots. About 93 men with recurrent prostate cancer will receive either SBRT alone or the drug first, then SBRT. …

This study tests a newer, highly precise radiation technique for men with high-risk prostate cancer. The treatment delivers a strong dose to the pelvic lymph nodes while boosting radiation to the prostate itself. Researchers want to see if this approach controls the cancer better…

This study is testing whether adding an immunotherapy drug (ONC-392) to a targeted radiation therapy (Pluvicto) can help men with a hard-to-treat form of advanced prostate cancer. About 148 participants whose cancer has worsened despite standard treatments will receive either a l…

This Phase 3 trial compares two hormone therapies (GnRH antagonist vs GnRH agonist) given alongside radiation for men with very high-risk localized or locally advanced prostate cancer. The main goal is to see which combination better delays cancer progression. The study enrolled …

This early-phase trial tests a new treatment for castration-resistant prostate cancer (CRPC), a type that no longer responds to standard hormone therapy. Researchers are injecting specially engineered immune cells (CAR-T cells) directly into the prostate or tumor site, after a sh…

This early-stage trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in people whose prostate, bladder, or kidney cancer has spread. The main goals are to find the safest dose and see what side effects occur. About 65 participants will receive both drugs t…

This phase 2 trial tests whether adding targeted radiation to standard hormone therapy can better control prostate cancer that has spread to a few spots in the body. About 29 men with hormone-sensitive prostate cancer and up to 5 metastases will receive hormone therapy (bicalutam…

This study tests whether adding the immunotherapy drug pembrolizumab can help men whose advanced prostate cancer has stopped responding to the standard drug enzalutamide. About 58 men with castration-resistant prostate cancer that has spread will receive pembrolizumab while conti…

This study aimed to see if giving the immunotherapy drug pembrolizumab before radical prostatectomy could reduce lymph node invasion in high-risk prostate cancer patients. Participants would have received three doses of the drug before surgery. However, the study was withdrawn be…

This Phase 2 trial tests an oral drug called ESK981 in people with advanced pancreatic cancer, neuroendocrine tumors, or neuroendocrine prostate cancer. The goal is to see if the drug can keep the cancer from growing for at least 4 months. Participants take the drug for 5 days, t…

This phase 3 trial compares the standard chemotherapy docetaxel alone versus docetaxel plus radium-223 in 732 men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if adding radium-223 helps patients…

This study looks at using heat or cold to destroy small clusters of prostate cancer that have spread to other parts of the body. It is for men who cannot have standard radiation therapy. The goal is to control the cancer with a quick, low-risk procedure that allows a fast recover…

This phase III trial compares two types of image-guided radiation for prostate cancer: CT-guided and MRI-guided stereotactic body radiotherapy (SBRT). About 179 men with localized prostate cancer will receive the same radiation dose, but one group's treatment is guided by CT scan…

This early-phase trial tests whether combining two oral targeted drugs, talazoparib and tazemetostat, is safe and can shrink or slow the growth of metastatic castration-resistant prostate cancer (mCRPC). About 35 adults with advanced prostate cancer that has spread and is no long…

This study tests a combination of two drugs, pembrolizumab and lenvatinib, in people with a rare and aggressive form of prostate cancer called neuroendocrine prostate cancer that has spread. The goal is to see if this treatment can slow or stop tumor growth. About 45 participants…

This early-phase trial tests whether giving higher doses of radiation to the prostate in fewer sessions (while also treating pelvic lymph nodes) is safe for men with intermediate- to high-risk prostate cancer. The study enrolls 18 adults and uses proton beam therapy delivered fou…

This study tests the drug olaparib in 51 men whose prostate cancer has returned after surgery and is at high risk of spreading. Olaparib works by blocking a repair process that cancer cells rely on, especially those with certain DNA faults. The main goal is to see if the drug can…

This study tests whether adding the immunotherapy drug atezolizumab and targeted radiation (SBRT) to standard hormone therapy (abiraterone, prednisone, and leuprolide) is safe and works better for men with newly diagnosed metastatic prostate cancer that hasn't been treated yet. T…

This phase 2 study tests nivolumab (Opdivo) in 29 men with high-risk prostate cancer that has returned after initial treatment, shown by rising PSA levels. The drug works by helping the immune system recognize and attack cancer cells. The main goal is to see if nivolumab can cont…

This trial gives men with metastatic castration-resistant prostate cancer (mCRPC) continued access to the experimental drug ZEN003694, often combined with enzalutamide (Xtandi), if they are already seeing benefits from it in a previous study. About 40 participants will be enrolle…

This phase 3 trial tests whether adding enzalutamide to standard hormone therapy and radiation can delay cancer spread in 802 men with high-risk localized prostate cancer. Participants receive either enzalutamide or a conventional anti-androgen alongside hormone therapy and radia…

This study looks at men whose prostate cancer has come back in a few spots (oligometastatic) and who have certain gene mutations. It compares standard care (hormone therapy plus radiation) against the same treatment plus a 6-month course of two drugs (niraparib and abiraterone wi…

This study was designed for men with high-risk prostate cancer who are scheduled for prostate removal surgery. It planned to give a combination of three immunotherapy drugs (N-803, ETBX-071, and M-CENK) both before and after surgery to see if it could help prevent the cancer from…

This study was designed for men with high-risk prostate cancer who cannot have surgery. It planned to combine three experimental drugs (N-803, ETBX-071, and M-CENK) with radiation to boost the immune system's attack on cancer. Researchers aimed to see if the treatment could elimi…

This study tests an experimental drug called ARV-766, taken as a pill, in men with prostate cancer that has spread to other parts of the body. The drug is given alone or with another medicine (abiraterone) to see if it is safe and can slow the cancer. About 152 men will take part…

This study tests whether adding darolutamide to standard hormone therapy and radiation can delay cancer spread in men with very high-risk localized prostate cancer. About 1,100 men are participating in this phase 3 trial. The goal is to see if the combination helps keep the cance…

This phase II trial tests whether using MRI to map the exact location of recurrent prostate cancer after prostatectomy allows doctors to safely deliver a higher radiation dose to the tumor while sparing healthy tissue. The study enrolled 37 men whose PSA levels rose after surgery…

This study tests a combination of a targeted drug (niraparib), hormone therapy, and precise radiation for men with high-risk or node-positive prostate cancer. The goal is to find the safest dose and see if this approach improves the chance of staying cancer-free for three years. …

This small study tests whether a 3D ultrasound system can help doctors place extra radioactive iodine seeds precisely into prostate tumors. Fifteen men with low- or intermediate-risk prostate cancer will receive the boost during standard brachytherapy. The main goal is to see if …

This early-stage study tests a radioactive drug called 225Ac-PSMA-617 in men with PSMA-positive prostate cancer that has stopped responding to hormone therapy. The goal is to find a safe dose and see if it can help control the cancer, even in men who have already received a simil…

This study tests a low dose of a radioactive drug called 225Ac-LNC1011 in 16 men with a type of advanced prostate cancer that has stopped responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly. The goal is to see if it safely shrin…

This study tests a combination of two radiation techniques—brachytherapy and SBRT—guided by MRI for men with unfavorable prostate cancer. The goal is to achieve high cancer control rates while keeping serious side effects low. About 40 participants will be enrolled to see if this…

This phase 2 trial tests a combination of hormone therapy, external beam radiation, and MRI-guided internal radiation implants for men with unfavorable-intermediate to very high-risk prostate cancer. The goal is to see if this precise approach causes fewer urinary side effects th…

This study looked at 70 men with an enlarged prostate and overactive bladder symptoms. Some received a Botox injection into the prostate during surgery, while others took standard medication after surgery. The Botox group showed better symptom scores at 12 weeks, suggesting a pot…

This study tests whether giving a mix of hormone-lowering medications (apalutamide, abiraterone, prednisone, and a GnRH drug) for a few months before surgery can shrink very high-risk prostate cancer and reduce the chance of it coming back. About 102 men with localized or low-vol…

This phase 2 trial is testing three different doses of a new drug called RS-113 in 120 men with metastatic castration-resistant prostate cancer, a type that has spread and no longer responds to standard hormone therapy. The study compares RS-113 to the current drug abiraterone to…

This trial was designed to test whether robotic telesurgery—where a surgeon operates a robot from a different location—could safely treat prostate cancer using high-intensity focused ultrasound (HIFU). The study was withdrawn before enrolling any participants, so no data on safet…

This study compares the targeted drug olaparib to two standard hormone therapies (enzalutamide or abiraterone) in Chinese men with advanced prostate cancer that has stopped responding to hormone treatment and who have BRCA1/2 gene mutations. The goal is to see if olaparib can del…

This study compares two types of brachytherapy (radiation implants) for localized prostate cancer: low-dose-rate (seed) implants and high-dose-rate (temporary) implants. About 334 men will receive one of the two treatments. Researchers will measure how well each controls cancer a…

This study tests a drug called ceralasertib, alone or with olaparib or durvalumab, in people with advanced solid tumors like kidney, bladder, pancreatic, and endometrial cancers. The goal is to see if these combinations can shrink tumors by blocking enzymes that help cancer grow.…

This study tests whether giving a higher dose of radiation (up to 81 Gy) to men with high-risk prostate cancer can better control the disease without causing too many side effects. About 251 men who also need hormone therapy will receive targeted radiation using a precise techniq…

This study looks at whether a special gene test can help men with low-risk prostate cancer decide to monitor their cancer instead of treating it right away. About 805 men with early-stage prostate cancer will be randomly assigned to have the gene test or not. The goal is to see i…

This study tests a precise form of proton radiation for men with low- or intermediate-risk prostate cancer. The goal is to see if this approach causes fewer severe side effects than standard X-ray-based radiation. About 61 men will receive 5 treatments over 10 days and be monitor…

This early-stage trial tests whether combining a targeted radiation drug (177Lu-PSMA-617) with chemotherapy (carboplatin) is safe and can shrink tumors in men with metastatic castration-resistant prostate cancer. About 37 men will receive the combination to find the best dose and…

This trial compares two common radiotherapy schedules for prostate cancer: 70 Gy in 28 sessions versus 60 Gy in 20 sessions. Both are already used in clinics, but it is not clear which one works better or causes fewer side effects. The study involves 400 men with early-stage pros…

This phase 2 trial is testing a combination of radium-223 (a radioactive drug that targets bone tumors), hormone therapy, and precise radiation for men with prostate cancer that has spread to a few other places in the body. The goal is to see if this triple approach can delay can…

This phase 2 trial tests whether a radioactive antibody called 177Lu-J591, combined with the hormone-blocking drug ketoconazole, can prevent prostate cancer from spreading in high-risk patients. The study enrolls 55 men whose PSA is rising despite hormone therapy but who have no …

This pilot study tests two ultra-high-dose radiation schedules in 31 men with intermediate-risk prostate cancer. One group gets five high-dose sessions over a week; the other gets a single massive dose. The goal is to see if these shorter treatments are safe and can control the c…

This early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…

This phase II trial tests whether adding the immunotherapy drug durvalumab to precise radiation (SBRT) can better control prostate cancer that has returned and spread to a few spots (oligometastases). About 96 men with hormone-sensitive prostate cancer will be randomly assigned t…

This phase 3 trial is testing whether adding local ablative therapy (radiation or surgery) to all visible cancer sites, on top of standard hormone therapy, improves outcomes for men with hormone-sensitive prostate cancer that has spread to a few spots (oligometastatic). About 409…

This study tests whether a combination of two drugs, olaparib and AZD6738, can shrink tumors or lower PSA levels in men with advanced prostate cancer that no longer responds to hormone therapy. About 49 men with metastatic castration-resistant prostate cancer will receive the dru…

This phase 2 study tests a radioactive drug called Lu-PSMA-617 against standard hormone therapy in 63 Chinese men with advanced prostate cancer that has stopped responding to treatment. The drug targets cancer cells with radiation. The goal is to see if it can delay cancer growth…

This early study tests a new treatment called RT-310 for men with enlarged prostate (BPH) who have bothersome urinary symptoms. RT-310 is a drug delivered directly into the prostate to reduce side effects. The study will check if it is safe and feasible in 20 men aged 50 to 80.

This study tests whether giving a precise, high-dose radiation treatment (SBRT) before prostate removal surgery is safe and effective for men with high-risk prostate cancer. Sixteen men with aggressive prostate cancer (Gleason score 8 or higher or signs of spread) will receive ra…

This study compares two drugs, mannitol and nitroglycerin, given during robotic prostate or bladder surgery to prevent acute kidney injury. The surgery can reduce blood flow to the kidneys, and these drugs may help protect them. 90 adults with normal or mildly reduced kidney func…

This study tests whether using a lung ultrasound during robotic prostate or bladder surgery can help doctors set the breathing machine to the right pressure, reducing lung collapse and other breathing problems. 88 adults with mild or no lung disease are enrolled. The approach is …

This study tests an experimental drug, YL201, in about 990 people with advanced solid tumors like lung, prostate, and liver cancers. The goal is to check safety and see if tumors shrink. It is an early-stage trial, so the drug is not yet proven to work.

This study tests whether a very short course of MRI-guided radiation (just 5 sessions) is safe and effective for men with low- or intermediate-risk prostate cancer. Traditional radiation can take 7-8 weeks, but this approach aims to cut that time dramatically. The trial involves …

This study tests whether using advanced MRI scans to guide radiation therapy can reduce side effects for men with localized prostate cancer. Depending on their MRI results, patients receive either a short course of radiation or a longer treatment with a targeted boost to visible …

This study looks at whether testosterone levels can return to normal after two years of treatment with relugolix and darolutamide in men with hormone-sensitive prostate cancer. About 33 participants will receive the drug combination and be monitored for testosterone recovery and …

This study tests a drug called palbociclib in 19 men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if it can shrink tumors or lower PSA levels, and to check for side effects. Researchers also look for markers to predict who might ben…

This study tests different combinations of approved drugs in 196 men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to see which combinations work best to extend life and control the cancer. Participants receive standard hormo…

This study tests whether using MRI guidance to deliver an extra dose of radiation directly to the tumor can improve prostate cancer treatment. Forty men with localized prostate cancer will receive standard radiation to the whole prostate plus a targeted boost to the visible tumor…

This phase 2 trial tests whether a shorter, more intense radiation course (SBRT) causes fewer side effects than standard daily radiation (IMRT) in men with high-risk prostate cancer. Both groups also receive hormone therapy. The study will compare side effects, quality of life, a…

This phase 2 study tests pembrolizumab (Keytruda) in 40 men with metastatic castration-resistant prostate cancer that has specific genetic flaws (mismatch repair deficiency or CDK12 inactivation). The goal is to see if the drug can shrink tumors or slow the cancer. Researchers wi…

This study tests whether giving radiation in just 5 treatments over 2 weeks is as safe and effective as the standard 20 treatments over 4 weeks for men whose prostate cancer has come back after surgery. The 134 participants will be randomly assigned to one of the two schedules. T…

This early-phase study tests whether a bicalutamide implant placed directly into the prostate can replace standard hormone shots for men with localized prostate cancer receiving radiation. About 20 participants with intermediate- or high-risk cancer will receive the implant plus …

This phase 1 trial is testing a precise, high-dose radiation technique called SABR for men with high-risk prostate cancer. The goal is to find the highest safe dose to the prostate and pelvic lymph nodes while monitoring side effects. Sixty participants will receive five radiatio…

This study tests whether giving an extra-high dose of radiation to the most aggressive parts of prostate tumors, guided by MRI, can better control cancer while reducing side effects. About 164 men with prostate cancer will receive either the standard radiation or the standard plu…

This study tests a special type of radiation called stereotactic body radiotherapy (SBRT) for men with high-risk prostate cancer that hasn't spread. The treatment delivers a strong, focused dose of radiation to the tumor to kill cancer cells while sparing healthy tissue. Research…

This study tests a combination of two drugs—cabazitaxel (a chemotherapy) and enzalutamide (a hormone blocker)—in people with prostate cancer that has spread and stopped responding to standard hormone therapy. The goal is to find the safest dose and see if the combination can lowe…

This early-phase study tests a new type of immunotherapy for men with advanced prostate cancer that no longer responds to hormone therapy. The treatment uses the patient's own immune cells, which are genetically modified to better recognize and attack prostate cancer cells while …

This study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …

This study tests a new way to deliver high-dose radiation (SABR) for low- and intermediate-risk prostate cancer. The technique, called SUPR-SABR, is designed to avoid the urethra, rectum, and pudendal artery to reduce urinary and bowel side effects. About 42 men will receive five…

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This study tests a radioactive drug called 225Ac-J591 in men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The first part finds a safe dose and schedule, and the second part checks if the drug lowers PSA levels by more than half. About 6…

This study aimed to see if taking antibiotics for three days after a type of prostate surgery (HoLEP) lowers the chance of getting a urinary tract infection. It was designed for men over 40 with an enlarged prostate and no current infection. However, the study was withdrawn befor…

This phase 2 trial tests enfortumab vedotin, a drug that targets cancer cells, alone or with other drugs in 34 men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if the drug can shrink tumors, low…

This study tests whether giving a combination of two hormone therapies (leuprorelin and darolutamide) for 24 weeks before prostate removal surgery can reduce or eliminate cancer more effectively than either drug alone. It involves 144 men with intermediate to high-risk prostate c…

This phase 2 trial is testing a combination of two hormone-based drugs—darolutamide and high-dose testosterone—in 51 men with metastatic castration-resistant prostate cancer, a form that no longer responds to standard hormone therapy. The approach, called extreme bipolar androgen…

This study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…

This phase III trial tests whether adding rucaparib to standard enzalutamide therapy helps men with metastatic castration-resistant prostate cancer live longer or delay cancer growth. The study involves 61 participants and compares the combination against enzalutamide alone. Rese…

This phase II trial is testing whether combining antiandrogen drugs (leuprolide, apalutamide, abiraterone) with precise radiation (SBRT) can control prostate cancer that has come back and spread to a few other spots in the body. The study enrolls 28 men whose cancer has 1-5 visib…

This study looks at whether men with a certain type of advanced prostate cancer (castration-resistant) who have inherited DNA repair gene mutations respond better to the chemotherapy drug carboplatin. Researchers will first screen participants for these genetic changes, then trea…

This phase II study tests whether giving an extra-high radiation dose directly to the main prostate tumor, while treating the rest of the prostate with standard SBRT, can reduce the chance of cancer coming back. About 91 men with intermediate-risk prostate cancer will receive fiv…

This study compares two radiation methods for men with low- or intermediate-risk prostate cancer: low dose rate (permanent seed implants) and high dose rate (temporary radioactive needles). The main goal is to see which approach better preserves urinary quality of life. About 140…

This study tests a robotic system that uses a high-pressure water jet to remove prostate tissue in men with localized prostate cancer and trouble urinating. The goal is to see if the procedure is safe and works well. About 125 men will be followed for one year after treatment.

This study compares three different radiotherapy techniques for prostate cancer: standard treatment, a shorter course (SBRT), and a booster approach. Over 500 participants are being followed to see which method best controls cancer while minimizing side effects and preserving qua…

This trial compares two types of brachytherapy boost (HDR vs LDR) given alongside external beam radiation for intermediate- and high-risk prostate cancer. The goal is to see which one provides better cancer control and quality of life with fewer side effects. About 195 men are ta…

This study compares a standardized active surveillance protocol to usual care for men with low-risk prostate cancer. The goal is to see if a clear set of rules for when to start treatment can reduce unnecessary treatments and side effects without raising the risk of cancer spread…

This study tests a new drug, NUV-1511, in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors in cancers like breast, prostate, pancreatic, and ovarian cancer. About 466 adults will ta…

This phase II trial tests whether using PSMA PET scans to select patients with castration-resistant prostate cancer that has spread to bones can improve the effectiveness of radium-223 therapy. Radium-223 is a radioactive drug that targets bone tumors. The study involves only 2 p…

This study looks at whether removing the prostate and nearby lymph nodes, in addition to standard drug therapy, helps men with prostate cancer that has spread to a few bones live longer and delay the cancer becoming resistant to treatment. About 452 men with intermediate- or high…

This study tests a new radioactive drug, 177Lu-HTK03170, designed to seek out and destroy prostate cancer cells that have spread. It is for men with metastatic castration-resistant prostate cancer whose disease has worsened after other treatments. The trial will first find a safe…

This study tests a new surgical technique for treating enlarged prostate in men who also have a penile implant. The standard approach through the urethra can damage the implant, so surgeons are trying an alternative route through the lower belly. The study will enroll 80 men and …

This study is for men whose prostate cancer has returned after surgery, shown by a rising PSA. It compares standard hormone therapy plus radiation to a stronger version that adds enzalutamide. The goal is to see if the enhanced treatment keeps the cancer from progressing longer. …

This trial is testing a new way to treat prostate cancer that returns after the prostate has been removed. It combines a very short course of highly targeted radiation (just 5 sessions) with 6 months of hormone therapy. The goal is to see if this approach can control the cancer w…

This phase 3 trial tests whether giving denosumab every 12 weeks instead of every 4 weeks can still prevent bone complications (like fractures or spinal cord compression) in people with metastatic breast or prostate cancer. About 1,380 participants with bone metastases will be ra…

This study looks at whether men whose metastatic prostate cancer has responded very well to hormone therapy can safely pause treatment. About 79 men will stop their medications under doctor guidance to see if their testosterone levels recover and they remain cancer-free for at le…

This phase 3 study tests whether combining two drugs—cabozantinib (a targeted therapy) and atezolizumab (an immunotherapy)—works better than standard hormone therapy for men with metastatic castration-resistant prostate cancer that has progressed after one prior hormone treatment…

This study tests whether adding a new drug (LY2157299) to the standard treatment enzalutamide can help men with advanced prostate cancer that has stopped responding to other treatments. About 60 participants will be randomly assigned to receive either the combination or enzalutam…

This study tests whether a daily high-dose omega-3 supplement (fish oil) can slow the rise of PSA levels in men whose prostate cancer has returned after initial treatment. About 40 men with a rising PSA but no spread will take either the supplement or a placebo for one year. The …

This study compares a newer hormone therapy (darolutamide) plus radiation against standard hormone therapy plus radiation for men with intermediate-risk prostate cancer. The goal is to see if the new approach controls the cancer just as well while helping men keep better erectile…

This early-phase trial tests whether combining two types of targeted radiation is safe for men whose prostate cancer has returned after prostate removal surgery. The treatment uses a special scan to find cancer cells, then delivers high-energy rays and a radioactive drug directly…

This pilot study is testing whether robot-assisted prostate removal for localized prostate cancer can be safely performed as outpatient surgery, meaning patients go home the same day. Twenty men will be enrolled and followed for one month to see if they can avoid a conventional h…

This study looks at whether adding a high-precision type of radiation called SBRT to usual cancer treatments (like hormone therapy or chemo) can delay cancer growth in people with breast, lung, or prostate cancer that has spread to 1 to 5 bones. About 168 adults aged 18-75 with g…

This early-phase trial is testing a combination of two immunotherapy drugs, naptumomab estafenatox and durvalumab, in 120 people with advanced or metastatic solid tumors like pancreatic, ovarian, and lung cancer. The main goal is to find a safe dose and see how the body reacts. R…

This early study tests a new device called RT-310, a small implant placed inside the prostate to treat bothersome urinary symptoms from an enlarged prostate. The trial includes 20 men aged 50 to 80 who have not gotten enough relief from medication. The main goal is to check if th…

This study looks at how well a new robotic surgery system (Medtronic Hugo) works for urologic procedures like removing prostate, bladder, or kidney tumors. About 144 adults will have surgery with the robot, and doctors will check if the surgery is completed without switching to a…

This early-phase study tested a combination of enzalutamide (a hormone-blocking drug), radiation therapy, and standard hormone therapy in 25 men with intermediate or high-risk prostate cancer. The main goal was to check for side effects and find the best way to give the treatment…

This phase 2 trial tests whether taking omega-3 (EPA) supplements can reduce inflammation and slow cancer cell growth in men with high-risk prostate cancer who choose surgery. 130 participants will take either EPA capsules or a placebo for 14 months, starting before surgery. Rese…

This study compares two types of radiation therapy for low- or intermediate-risk prostate cancer in Asian men. One method, SBRT, delivers high-dose radiation in fewer sessions, while the other, IMRT, uses more standard daily doses. The main goal is to see which approach better pr…

This early-phase trial tests whether adding the immunotherapy drug pembrolizumab to standard platinum-based chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. The study includes 15 participants whose cancer has spre…

This study looks at whether a special type of radiation called stereotactic body radiotherapy (SBRT) can help prevent prostate cancer from coming back after surgery. About 92 men who had their prostate removed and have signs of remaining cancer will receive SBRT. The goal is to s…

This phase 2 trial is testing whether a shorter course of hormone therapy (6 months instead of the usual longer duration) combined with targeted radiation can safely prevent high-risk prostate cancer from spreading. About 50 men with aggressive prostate cancer will receive hormon…

This phase 2 trial tests whether a radioactive tracer called 18F-DCFPyL can improve PET/CT scans for men with high-risk or recurrent prostate cancer. About 360 men will receive the tracer and undergo imaging to see if it more accurately finds cancer outside the prostate or after …

This study compares a new radioactive tracer called 18F-DCFPyL with standard tracers to see if it can better detect where prostate cancer has spread in the body. About 96 men with metastatic prostate cancer will receive both tracers and undergo PET/CT scans. The goal is to measur…

This study tests a new type of PET/CT scan using a radioactive tracer called copper Cu 64 PSMA I&T to see if it can accurately find prostate cancer that has spread to pelvic lymph nodes. About 439 men with newly diagnosed, aggressive prostate cancer who are planning to have their…

This study is testing whether a type of PET scan called PSMA PET is more accurate than standard scans (like CT or bone scans) for monitoring prostate cancer. About 58 men with progressive prostate cancer will receive an injection of a radioactive tracer and then undergo PET/CT im…

This study is testing a new blood test that looks at RNA from tiny particles called exosomes to diagnose prostate cancer. Researchers will enroll 1,600 men with elevated PSA levels or other signs of prostate cancer. The goal is to see if this test can accurately detect cancer and…

This study is testing whether a new blood test called ClarityDX Prostate can better identify men who have clinically significant prostate cancer. The test is given to men aged 40-75 with elevated PSA levels (3 ng/mL or higher) who are already scheduled for a prostate biopsy. Rese…

This trial tests whether combining a blood test that analyzes DNA fragments (cfDNA) with MRI scans can better detect prostate cancer in men with borderline PSA levels (4–10 ng/mL). Researchers aim to build a prediction model that could reduce unnecessary biopsies. The study invol…

This trial is testing whether a blood-based risk score called ClarityDX Prostate can help doctors decide which men truly need an MRI or biopsy when checking for prostate cancer. The test combines standard PSA levels with age and other factors to give a personalized risk estimate.…

This study compares two imaging methods—multiparametric ultrasound (mpUS) and multiparametric MRI (mpMRI)—to see which better detects clinically significant prostate cancer in men scheduled for their first biopsy. Participants receive both scans before biopsy, and if either shows…

This study tests a new imaging agent called 68Ga-FAPI-46, which targets a protein (FAP) found around tumor cells. Researchers want to see where this tracer goes in the body and whether it can highlight prostate cancer on PET scans. About 30 people with prostate cancer who are alr…

This study tests whether a new radioactive tracer called 68Ga-HBED-CC-PSMA can detect prostate cancer that has returned after initial treatment, even when PSA levels are very low and standard scans show nothing. Men with biopsy-proven prostate cancer who have been treated with su…

This study aims to develop an artificial intelligence (AI) model that combines two advanced imaging techniques—multiparametric MRI and PSMA PET/CT—to more accurately diagnose prostate cancer. By analyzing data from up to 1,500 patients, the AI model is designed to identify clinic…

This trial evaluates a new imaging technique called 18F-PSMA-1007 PET/CT for detecting prostate cancer in men with elevated PSA levels (4-20 ng/mL) or abnormal rectal exams. The scan uses a radioactive tracer that targets a protein common on prostate cancer cells, aiming to impro…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study looks at whether a special PET scan called Axumin can find prostate cancer that has returned after treatment, even when another common scan (PSMA PET) shows nothing. About 50 adults with rising PSA levels and a negative PSMA PET will get an Axumin scan. The goal is to …

This study tests an artificial intelligence system that combines blood tests, lab data, and ultrasound images to better diagnose prostate cancer in men with borderline PSA levels (4-10 ng/mL). The goal is to reduce unnecessary biopsies by accurately identifying who truly has canc…

This study tests whether combining a special MRI analysis (called Habitat Risk Score) with blood and urine tests can more accurately rule out aggressive prostate cancer than the standard MRI reading. About 289 men with elevated PSA or abnormal exams will be enrolled. The goal is …

This study aimed to see if adding a two-minute distortion correction to standard prostate MRI scans could improve image quality and help doctors find tumors more accurately. It was designed for men who already had an MRI and biopsy. However, the study was withdrawn before any par…

This trial compares two biopsy methods for diagnosing prostate cancer in African American and white men with elevated PSA. One group gets a standard 12-core random biopsy, the other gets an MRI-guided fusion biopsy. The goal is to see which method more accurately detects clinical…

This study tests whether a new PET-CT scanner (RefleXion RMRS) can produce clear images of prostate cancer using a standard radioactive tracer. About 34 patients will receive both the standard scan and the new scan. If the new scanner works well, it may allow imaging and radiatio…

This study tests whether a special PET/CT scan (68Ga-PSMA-11) can help doctors plan more precise radiation for men whose prostate cancer has come back after surgery. About 193 men with a rising PSA level will be randomly assigned to have their radiation plan based on either the n…

This phase 3 study tests a new type of PET scan (64Cu-SAR-bisPSMA) to see if it can better detect prostate cancer that has come back after initial treatment. The study involves 220 adults with a rising PSA level after surgery or radiation. The goal is to improve detection so doct…

This study is testing a new imaging method called Cerenkov luminescence imaging, which uses light naturally given off by certain radioactive substances used in standard cancer scans. Researchers want to see if this technique can take clear pictures of thyroid cancer and tumors th…

This early-phase trial tests TRDC002, a radioactive tracer that attaches to PSMA proteins on prostate cancer cells, to improve PET/CT imaging in patients whose cancer has returned or spread. Six adults with PSMA-positive recurrent or metastatic prostate cancer will receive a sing…

This study tests whether a special PET/CT scan using a radioactive tracer called 18F-DCFPyL can better detect aggressive prostate cancer in men with elevated PSA levels. About 150 men with PSA between 2-10 ng/mL and no prior biopsy will receive the scan before their standard biop…

This study looks at the best timing for a special PET scan (rhPSMA-7.3) to detect prostate cancer that has come back after prostate removal surgery. Men with a rising PSA level will get one or two scans to see when the cancer is most visible. The goal is to find the cancer early …

This study compares two types of urine samples—expressed prostatic secretion (EPS) and post-massage urine (PMU)—to see which one better predicts whether a prostate biopsy will find cancer. About 243 men scheduled for a prostate biopsy will provide both samples, and researchers wi…

This early study tests a new imaging agent called 89Zr-DFO-YS5, which attaches to a protein (CD46) found on aggressive prostate cancer cells. Thirty men with advanced prostate cancer will receive the agent and then undergo PET scans to see if the cancer lights up. The goal is to …

This pilot study is testing the world's first total-body PET/CT scanner (EXPLORER) to see if it can improve cancer imaging. Researchers will scan 9 people with prostate cancer, breast cancer, or neuroendocrine tumors using FDA-approved radiotracers. The goal is to measure how wel…

This pilot study is testing a new screening pathway for prostate cancer in men aged 55-65. Instead of relying only on PSA blood tests, participants with elevated PSA will also get a risk assessment and an MRI. The goal is to better distinguish between slow-growing cancers that do…

This study looks at whether combining PSMA-PET/CT and MRI scans can more accurately determine the extent of prostate cancer in men with intermediate- or high-risk disease. Researchers will compare scan results with tissue samples from 600 men who had their prostate removed. The g…

This study tests whether adding a PSMA PET scan helps doctors better diagnose significant prostate cancer in men whose MRI results are unclear or negative. About 660 men with no prior prostate cancer or biopsy will be randomly assigned to receive either standard care or an additi…

This study tests whether analyzing ultrasound images with computer software (radiomics) can better predict prostate cancer during a targeted biopsy. About 464 men aged 55 and older with suspicious prostate findings will participate. The goal is to see if this method finds more ca…

This study tests a special PET scan (18F-DCFPyL) to see if it can find prostate cancer spread that standard scans miss. Fifty men with castration-resistant prostate cancer starting enzalutamide will get the new scan. The goal is to better detect and monitor metastases, which coul…

This study looks at whether men with certain gene mutations (DRG) could benefit from a more tailored screening for prostate cancer. Researchers will test a combination of a blood test (PHI) and a special MRI scan in 320 men with or at risk for prostate cancer. The goal is to see …

This study tests a new software that combines MRI images with real-time ultrasound to guide prostate biopsies. The goal is to help doctors more accurately detect and locate aggressive prostate cancer early. About 100 men scheduled for a standard prostate biopsy will take part. Th…

This early-stage study tests an experimental vaccine designed to prevent cancer in adults with BRCA1 or BRCA2 gene mutations. The vaccine is given alone or with another drug, followed by a mild electric pulse to help it enter cells. Researchers want to see if it is safe and wheth…

This study looks at whether eating more omega-3 fatty acids (like those in fish oil) and taking a drug called dutasteride can slow the growth of low-risk prostate cancer. The 120 participants are men on active surveillance, meaning their cancer is being watched rather than treate…

This study tests a telemedicine program called FOCUS that helps advanced cancer patients manage common symptoms like trouble sleeping, worry, tiredness, and low mood. The program uses counseling techniques delivered through a phone app. Researchers will enroll 120 adults with adv…

This phase II trial tests whether time-restricted eating (intermittent fasting) can reduce side effects from radiation or chemoradiation in people with prostate, cervical, or rectal cancers. About 49 participants will either follow a time-restricted eating plan or receive standar…

This trial tests a biodegradable gel called SpaceOAR Vue that is injected between the prostate and rectum before radiation therapy. The gel temporarily pushes the rectum away to reduce radiation damage. About 500 men with intermediate-risk prostate cancer will be randomly assigne…

This phase 2 study tests whether acupuncture can improve memory, focus, and thinking problems (often called 'chemo brain') in people who have had breast, colorectal, prostate, or gynecological cancer. About 48 participants will receive either real acupuncture or sham (fake) acupu…

This pilot study tests a lifestyle intervention called Watchful Living for Black and Hispanic prostate cancer patients on active surveillance and their partners. The program includes nutrition counseling, an exercise plan, and telephone coaching to improve quality of life, physic…

This study looks at whether combining exercise, supportive counseling, and a stimulant drug (methylphenidate) can help reduce severe fatigue in prostate cancer patients who are receiving radiation and hormone therapy. About 175 adults with prostate cancer and daily fatigue will b…

This study tests the DISCO app, designed to help cancer patients talk with their doctors about treatment costs. About 254 adults newly diagnosed with breast, prostate, lung, or colorectal cancer will use the app to become more confident in asking cost-related questions. The goal …

This trial tests a device called the Optilume BPH Catheter System, a balloon coated with the drug paclitaxel that is inflated inside the prostate to widen the urinary passage. The study enrolls men aged 50 to 80 with moderate to severe BPH symptoms who have not responded well to …

This study tests a device called the ProVee Urethral Expander, which is placed in the prostate to open the urinary channel and relieve symptoms of an enlarged prostate. About 221 men with moderate to severe symptoms are enrolled, and the device is compared to a sham procedure. Th…

This study looks at whether people with breast or prostate cancer that has spread to the bones can safely stop or reduce their bone-strengthening medication after taking it for at least two years. The goal is to see if this change improves their quality of life without increasing…

This study compares group telemedicine appointments to individual video visits for men with prostate cancer who are on active surveillance. Researchers want to see if the group format is practical and acceptable, and how it affects patient satisfaction and quality of life. The st…

This study tests whether a 12-week home exercise program, guided by telehealth check-ins, can reduce fatigue in cancer survivors living in rural Colorado. Participants follow a personalized plan of aerobic and resistance exercises, with intensity adjusted based on their progress.…

This study tracks 500 men with symptomatic benign prostatic hyperplasia (BPH) who receive the Optilume BPH Catheter System in real-world clinics. The goal is to see how well the device eases urinary symptoms and how safe it is over 12 months. Participants must follow contraceptio…

This trial tests whether an AI-powered chatbot can help reduce anxiety and improve coping in men about to have prostate cancer surgery. Participants will either receive standard preoperative communication or also have access to a large language model (LLM) that answers their ques…

This study tests whether adding an extra numbing injection inside the prostate can reduce pain during a prostate biopsy. Fifty men undergoing the procedure will receive either standard numbing of the skin or the standard plus the extra injection. Pain levels are measured before, …

This study tests whether using advanced MRI and daily CT scans during radiation therapy for low- to intermediate-risk prostate cancer can reduce side effects like bowel, bladder, and erectile problems. About 99 men will receive standard radiation but with more precise imaging to …

This study tests whether a structured home-based exercise program combining strength and aerobic training can improve quality of life, fitness, and immune function in 150 men with prostate cancer. Participants are randomly assigned to either the exercise program or usual care. Th…

This study tests whether eating a low-calorie diet before chemotherapy can reduce side effects like fatigue, nausea, and mouth sores, and also improve how well the treatment works. About 130 people with breast or prostate cancer will be randomly assigned to either follow the diet…

This study looks at whether men with prostate cancer can have robotic surgery to remove the prostate and go home the same day, instead of staying in the hospital overnight. Researchers will check how many patients agree to try this approach and how well it works. The goal is to s…

This phase 2 trial is testing whether a special type of radiation therapy (SAbR) that avoids the nerves involved in erections can help preserve sexual function in men with localized prostate cancer. About 124 men will be randomly assigned to receive standard SAbR or a version tha…

This study compares standard robotic prostate cancer surgery with or without an extra step called vesicopexy, which repositions the bladder to its normal place. The goal is to see if this addition helps men regain bladder control faster and improves their quality of life. About 1…

This study tests a new device designed to relieve symptoms of an enlarged prostate, such as frequent or difficult urination. About 245 men aged 50 and older will be randomly assigned to receive the device or a sham procedure. The main goal is to see if the device improves symptom…

This study tests a new radiation technique for men whose prostate cancer returns after surgery. Instead of many standard treatments, this approach uses daily scans to adjust the radiation beam precisely, potentially reducing side effects and shortening the number of sessions. Abo…

This study tests whether a personalized 4-week exercise program can improve quality of life and physical function in men with metastatic prostate cancer who are receiving radiation therapy. Eighty participants will either exercise or not, and researchers will track changes in wel…

This study looks at two non-drug ways to help older men with an enlarged prostate. It compares electromagnetic field therapy, a gentle treatment using energy waves, to aerobic exercise like walking or cycling. The goal is to see which works better to shrink the prostate and ease …

This study looks at whether giving a numbing injection (called a TAP block) early or late during robotic prostate surgery helps reduce pain afterward. About 94 men with prostate cancer will take part. The goal is to find the best timing to lower pain scores and the need for stron…

This study looks at two procedures—prostate artery embolization (PAE) and holmium laser enucleation (HoLEP)—to see which better eases urinary symptoms caused by an enlarged prostate. It involves 45 men aged 50 or older with prostates larger than 80 grams. The main goal is to meas…

This study tests a personalized rehabilitation program designed to help men recover their sexual quality of life after prostate removal for cancer. About 135 men will take part, with half receiving the program and half receiving standard care. The goal is to see if the program im…

This study aimed to see if a 12-week supervised exercise program could improve quality of life and physical fitness in men with advanced prostate cancer receiving hormone therapy. Participants would have been randomly assigned to either the supervised program or usual care with e…

This study looks at whether doing pelvic floor exercises before prostate surgery can help men avoid urine leakage afterward. About 30 men with an enlarged prostate will either do exercises before surgery or get standard care. The goal is to see if patients and doctors find the ex…

This study looks at whether giving men a deeper level of muscle relaxation during robotic prostate surgery can lower the pressure used during the operation and reduce pain afterward. About 139 men having this surgery will be randomly assigned to either deep or moderate muscle rel…

This study tests whether giving magnesium sulfate during prostate surgery can lower pain and reduce the need for strong painkillers. About 68 adults having robotic prostate surgery will either receive magnesium or not, as part of their standard anesthesia. Researchers will compar…

This trial tests whether having an empty bladder before CT simulation for prostate cancer radiation therapy is better than the usual full bladder. The goal is to see if it reduces urinary symptoms and makes daily treatments more consistent. About 168 men with prostate cancer will…

This study tests whether a special cooling mat can reduce hot flashes and night sweats in people taking hormone therapy for breast or prostate cancer. About 40 participants will use the mat for 8 weeks and track their symptoms. The goal is to see if this simple, non-drug approach…

This study planned to compare two types of pelvic floor rehabilitation for men who still have urinary incontinence more than a year after prostate removal. One method uses standard Kegel exercises, while the other focuses on whole-body postural control. The goal was to see which …

This study tests a new way to give radiotherapy for men with intermediate-risk prostate cancer. The goal is to lower the dose to healthy parts of the prostate while boosting the dose to the tumor, using a special MRI-guided machine (MR-linac). Twenty men will take part to see if …

This study tests whether placing a Urolift device in the prostate before stereotactic body radiation therapy (SBRT) can reduce urinary side effects like frequent urination, pain, and nighttime trips to the bathroom. About 20 men with both prostate cancer and benign prostatic hype…

This study tests whether eating only within a 10-hour window each day can help prevent frailty in people over 55 who are on hormone therapy for prostate cancer. Frailty makes it harder to recover from stress and can lead to loss of independence. The trial will enroll 30 participa…

This study tests whether a gentle electrical current applied to specific points on the skin (AcuTENS) can reduce pain and anxiety during a prostate biopsy. About 53 men having their first biopsy will receive either active AcuTENS or a placebo device, on top of standard numbing me…

This study looks at whether adding tramadol or magnesium to a standard local anesthetic (ropivacaine) for a nerve block can better control pain during and after robotic prostate removal. Ninety men aged 40-80 will be randomly assigned to receive one of three solutions: ropivacain…

This study tests whether a live, personalized exercise and meditation coaching program, delivered through a digital app, can improve the quality of life for cancer survivors. The trial involves 146 adults who have had breast, lung, prostate, colorectal, or other cancers. Particip…

This study looks at whether starting pelvic floor physical therapy before prostate surgery (HoLEP) helps men regain bladder control more quickly after the procedure. About 72 men who are already scheduled for HoLEP to treat an enlarged prostate will be randomly assigned to start …

This early-stage study tests a high-precision radiation treatment called stereotactic body radiation therapy (SBRT) for men whose prostate cancer has returned after surgery. The main goal is to find the safest dose by monitoring side effects in 26 participants. The treatment deli…

This study follows over 64,000 adults who grew up on farms to see if early exposure to pesticides and other agricultural factors is linked to cancer. Participants fill out an online questionnaire and may provide biological samples. Researchers will track their health over many ye…

This study follows nearly 90,000 farmers, their spouses, and pest control workers in Iowa and North Carolina over many years. Researchers track their exposure to pesticides and other farm chemicals, then monitor who develops cancer or other diseases. The goal is to identify which…

This study is testing whether regular screening for prostate, lung, colorectal, and ovarian cancers can reduce deaths from these diseases. About 154,900 men and women aged 55-74 were randomly assigned to either get screened or receive usual care. Researchers are tracking cancer c…

This study looks for genetic changes that raise the risk of prostate cancer, especially in men diagnosed young or with a family history. Over 23,800 men with prostate cancer provided DNA samples. The goal is to find inherited genes linked to the disease, which could improve risk …

This study looks at how safe and doable different amounts of aerobic exercise are for people about to have surgery for solid tumors like breast, endometrial, or prostate cancer. About 60 participants will exercise at home while using apps and devices to track their activity. The …

This study looks at whether combining a genetic test called the Genomic Prostate Score (GPS) with MRI scans can help doctors better choose men with prostate cancer for focal therapy, which treats only the cancerous part of the prostate. Researchers will analyze data and tissue sa…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study looks at how the brain and pelvic floor muscles work together in men who have had or are having robot-assisted prostate surgery for prostate cancer. By recording brain activity (EEG) and muscle activity (EMG) during urination and Kegel exercises, researchers hope to id…

This study looked at whether regular screening tests for prostate, lung, colorectal, and ovarian cancers can help find cancer early and reduce deaths. Over 76,000 men and women took part, with some getting screened and others receiving usual care. The main goal was to see if scre…

This study tests whether low-intensity electrical stimulation of nerves near the prostate can help surgeons monitor and preserve erectile function during robot-assisted prostate removal. Twenty men with localized prostate cancer and normal erectile function will receive the stimu…

This trial tests whether an artificial intelligence program can automate two key steps in radiotherapy planning: outlining areas at risk of tumor spread or radiation damage, and designing the radiation beams. The AI tool is compared against the standard manual process done by onc…

This study looks at inherited gene changes (like BRCA) in men with prostate cancer to understand how common they are and how they affect treatment. Researchers will collect saliva samples and health information from 1,360 men in Washington state. The goal is to improve cancer car…

This study looks at tissue and blood samples from men with and without prostate cancer to find genetic changes linked to the disease. Researchers hope to learn what causes prostate cancer at the molecular level. The goal is to use this knowledge to develop better screening tests …

This study looks at men who had their prostate removed for cancer at least one year ago. Researchers want to understand how common and severe problems like urine leakage and erectile dysfunction are, and how these issues affect quality of life, self-esteem, and relationships. Par…

This study follows people who have received photodynamic therapy (PDT) for various cancers, including head and neck, lung, and skin tumors. PDT uses a light-sensitive drug and a special light to destroy cancer cells while sparing healthy tissue. Researchers will review medical re…

This study explores whether a genetic test can identify prostate cancer patients at higher risk for urinary side effects from radiation therapy. Researchers will track side effects in 208 men with early-stage prostate cancer who receive stereotactic radiation. The goal is to see …

This study looks at how men with low-risk prostate cancer and their partners or close allies decide on treatment. Researchers want to understand how anxiety and uncertainty influence these choices. About 541 participants will fill out questionnaires about their feelings and prefe…

This study looks at prostate cancer tissue from men undergoing prostate removal surgery to find cells that may be especially aggressive and resistant to treatment. Researchers give a special dye (pimonidazole) before surgery to mark oxygen-starved areas, then analyze the removed …

This study tests a new type of MRI that uses a special substance (hyperpolarized pyruvate) to see how active prostate cancer tumors are. Researchers want to know if this scan can find aggressive cancers and show if treatments are working or stopping sooner than standard scans. Ab…

This study looks back at the records of 625 men who had robotic prostate surgery for localized prostate cancer. It compares a newer single-port method with the standard multi-port approach to see which leads to fewer complications and better urinary control. The goal is to gather…

This study looks at how men weigh the benefits of improved urination against changes in sexual function after a prostate surgery called HoLEP. Researchers will interview participants and ask them to complete questionnaires over two years. The goal is to understand what matters mo…

This study is testing whether artificial intelligence can predict if prostate cancer has spread to lymph nodes or other parts of the body by analyzing biopsy tissue images. Researchers will use samples from 3,000 men to develop and validate the AI model. The goal is to help docto…

This study is developing an artificial intelligence model to predict which patients with advanced prostate cancer are at higher risk of developing a more severe form called castration-resistant prostate cancer. The AI will analyze MRI images, biopsy slides, and clinical data from…

This study tests new ways to help rural primary care clinics provide better follow-up care for cancer survivors. Researchers will give clinics telementoring, quality improvement coaching, and an obesity management toolkit. The goal is to see if these tools help clinics follow nat…

This study was designed to see how accurately patients report their own medication and healthcare use in diaries compared to official health insurance records. It planned to include people with diabetes, arthritis, kidney disease, or prostate cancer. However, the study was withdr…

This study follows 214 men treated for prostate cancer to see how many develop lower limb lymphedema (leg swelling) and who is most at risk. Participants attend check-ups every three months for 18 months. The goal is to better understand this side effect and its impact on quality…

This study examines 15 proteins on prostate cancer cells from 1,600 patients to see which ones are common and whether they relate to survival. Researchers will analyze stored tissue samples and collect new ones from men with advanced cancer. The goal is to understand these protei…

This study looks at how genetic differences (SNPs) in prostate cancer patients affect their response and side effects to the drug abiraterone. Researchers will analyze DNA from 600 patients taking abiraterone plus prednisone and bicalutamide. The goal is to find genetic markers t…

This study tests whether a program that educates and supports doctors can help them follow national guidelines for prostate cancer imaging. About 58 VA doctors and staff took part. The goal is to reduce inappropriate scans for low-risk patients and ensure appropriate scans for hi…

This study tests a new way of organizing care for people aged 70 and older who have cancer (breast, lung, colorectal, or prostate) plus at least one other serious health condition. The GERONTE program brings all their doctors and nurses together using a shared digital care plan. …

This pilot study looks at whether special scans (PSMA PET/MRI) and genetic tests can predict how well high-risk prostate cancer responds to hormone therapy and radiation. Thirty participants will be followed for up to 5 years. The goal is to find markers that identify poor respon…

This study tests whether artificial intelligence can help doctors outline the prostate on ultrasound images for a type of radiation treatment called brachytherapy. Thirty-six adults with prostate cancer will have their treatment plans made both with and without AI assistance. The…

This study involves 400 men with high-risk prostate cancer who have not yet received treatment. Researchers are using a special type of scan called PSMA PET to see if it can find cancer that has spread to lymph nodes or other parts of the body, which standard scans often miss. Th…

This study tests a small implantable device that is placed inside prostate tumors to see how they respond to different cancer drugs. About 35 men scheduled for prostate removal surgery will receive the device before their operation. The goal is to learn whether this approach is s…

This study aimed to see if a specially designed website could help men with low-risk prostate cancer understand their treatment options and feel more confident in their choices. The researchers planned to enroll patients and measure their knowledge and decision-making satisfactio…

This observational registry will follow 500 men with metastatic castration-resistant prostate cancer who are receiving PSMA theranostics (177Lu-PSMA) as part of their standard care. Researchers will track how well the treatment lowers PSA levels and monitor any serious side effec…

This study compares infection rates in 300 men undergoing transperineal prostate biopsy, half receiving antibiotics and half not. The goal is to see if omitting antibiotics is safe. If proven, it could reduce unnecessary antibiotic use and side effects.

This research study collects tissue, blood, and other samples from 2,400 people diagnosed with breast, colon, kidney, liver, multiple myeloma, or prostate cancer at a young age. The goal is to identify genetic changes that may explain why these cancers occur early, especially in …

This study looks at survival rates for people with cancers like melanoma, breast, colon, and lung cancer using data from Russian cancer registries. It includes 100,000 people of any age. The goal is to understand survival trends to help improve cancer care, not to test a new trea…

This study, called PARADIGM, is not testing a new drug. Instead, it looks at whether analyzing DNA from a blood sample can tell doctors which standard treatment—like hormone therapy or chemotherapy—will work best for a patient with metastatic prostate cancer. Researchers will tak…

This study tests a web-based tool called WellPrept that gives patients clear information before their urology procedures. Researchers want to see if it helps patients feel more confident and understand their condition better, and if it shortens clinic visits. About 300 men and wo…

This pilot study tests a new MRI technique that uses a special form of bicarbonate to measure how acidic prostate tumors are. Ten men with localized prostate cancer will receive an injection of hyperpolarized bicarbonate before an MRI scan. The goal is to see if this method is sa…

This study looks at whether hormone therapy (like Lupron or Casodex) changes thinking abilities in men aged 65 and older with prostate cancer. Researchers will compare cognitive function over time between men starting hormone therapy, those who have never had it, and those who ha…

This study looks at whether a 12-week survivorship program for men with advanced prostate, kidney, bladder, testicular, or penile cancer can be successfully added to their regular follow-up care. Researchers will measure how feasible and acceptable the program is using questionna…

This study follows 120 men who had robot-assisted surgery for prostate cancer to see how they are doing 10 years later. Researchers will check if the cancer has come back, how common incontinence and erectile dysfunction are, and how satisfied patients feel. The goal is to unders…

This study looks at whether a special PET scan called Posluma can help doctors plan radiation therapy more precisely for prostate cancer. About 20 patients will get both a standard PET scan and an extra scan on the RefleXion X1 machine. The goal is to see if the new scan finds th…

This study is looking at tiny particles called extracellular vesicles that come from prostate cancer cells. Researchers want to see if levels of these particles in blood and urine can show how well surgery removed the cancer. They will compare samples from prostate cancer patient…

This study examines DNA from over 21,000 cancer patients in New York to find gene changes linked to several cancers, including breast, colon, and lung. Researchers will compare these genes to those from healthy people to spot differences. The goal is to generate ideas for future …

This study follows 304 men in Martinique diagnosed with prostate cancer from 2020 onward. Researchers use digital questionnaires to track changes in quality of life, especially sexual and urinary issues. The goal is to gather data to improve care and reduce health gaps in the Car…

This study tests a web-based education tool called HOPE-Genomics that teaches cancer patients about their genetic test results. About 465 adults with breast, colorectal, lung, ovarian, pancreatic, or prostate cancer are taking part. The goal is to see if the tool helps patients r…

This study looks at how hormone therapy (anti-androgen treatment) for prostate cancer affects the heart. Researchers will use heart MRI scans before and after 4-7 months of treatment in 23 men. The goal is to understand changes in heart function, not to treat the cancer itself.

This study follows 200 men with prostate cancer who are receiving hormone therapy (androgen deprivation therapy) for at least 6 months. Researchers want to understand how this treatment affects the heart over time, and how factors like medical history, race, income, and access to…

This study looks at whether detailed analysis of MRI scans (called radiomics) can better predict how aggressive a prostate cancer is and whether it will come back soon after surgery. Researchers will study 125 men with prostate cancer who have an MRI before treatment. The goal is…

This study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affec…

This study follows 490 men with low-risk prostate cancer in Brazil to see how well active surveillance works. Active surveillance means closely monitoring the cancer instead of treating it right away. The goal is to learn how often the cancer changes and how many men avoid treatm…

This study looks at how often prostate cancer survivors experience faecal incontinence (loss of bowel control) after a specific type of radiation therapy. Researchers will track 200 survivors and measure the radiation dose received by the anal sphincter to see if higher doses lea…

This study follows 178 patients who previously received an AvenCell CAR-T cell therapy for cancers like lymphoma, leukemia, or prostate cancer. Researchers will track delayed side effects, including new cancers or autoimmune issues, for years. No new treatment is given—this is pu…

The RELIEF study was designed to compare different treatments for an enlarged prostate (BPH) in everyday medical practice. It planned to follow patients who received the UroLift implant, other surgeries, or medication/watchful waiting. However, the study was withdrawn before enro…

This study collects tissue, blood, and other fluid samples from men with prostate conditions, including those with no cancer, localized disease, or advanced stages. Researchers will analyze genetic changes and protein markers to understand why some men get prostate cancer, why so…

This pilot study tests whether a smartphone app called Prostate Cancer Genius can help African American men learn about prostate cancer and complete a home-based PSA test. Eighty men aged 55 to 69 from Oklahoma who haven't had a PSA test in two years will use either the new app o…

This study follows 250 men with prostate cancer who are receiving radiotherapy. Researchers want to see if a person's 'sense of coherence' — their ability to cope with stress — is linked to their quality of life and how they rate their own health. Participants fill out questionna…

This study aimed to collect prostate tissue samples from men undergoing brachytherapy for prostate cancer. The goal was to build a biobank for research into how the cancer responds to radiation. No participants were enrolled, and the study was withdrawn before it began.

This study was designed to see how much information people with breast or prostate cancer can recall about their screening and diagnosis. Researchers planned to give participants access to their online medical records and then test if that helped them remember more accurately. Ho…

This study looks at how certain hormone therapies for advanced prostate cancer might affect memory, thinking, and brain structure. Researchers will use brain scans and thinking tests in 100 men to track changes over time. The goal is to understand which patients are more likely t…

This study was designed to test whether using smaller or larger stitches during robotic prostate surgery helps men regain bladder control faster. It planned to enroll men with prostate cancer undergoing robotic prostate removal. However, the trial was withdrawn before any partici…

This study looks at whether standard hormone therapy (apalutamide, darolutamide, or enzalutamide) can increase the visibility of prostate cancer cells on PSMA PET/CT scans. About 9 men with recurrent prostate cancer will take the hormone pill for a few weeks and then get a scan. …

This study looks at new ways to predict how prostate cancer and nearby healthy tissues react to a precise type of radiation therapy called SBRT. Researchers will analyze breath samples, blood DNA, and CT scans from 60 men with low- or intermediate-risk prostate cancer. The goal i…

This study looks at whether non-invasive tests—like blood, urine, and genetic analysis—can help track prostate cancer progression without repeated biopsies. Researchers will follow 500 men with low, intermediate, or high-risk prostate cancer as they receive standard care. The goa…

This study tests a method called KIM that tracks the prostate's position during radiation using implanted gold markers. If the prostate moves more than 3mm, the radiation beam stops and is repositioned. The goal is to see if this technique is feasible in 100 men receiving radiati…

This study aims to find better ways to detect prostate cancer by looking at blood samples. Researchers will test special antibodies to see if they can identify cancer markers in circulating tumor cells. The study includes 40 men with prostate cancer and 20 healthy donors. It is a…

This study follows over 96,000 Seventh-day Adventists in the U.S. and Canada to see how diet and lifestyle choices relate to breast, colorectal, and prostate cancer. Researchers are focusing on intakes of meat, soy, and dairy. Because it is observational, it can show patterns but…

This observational study looks at why hormone therapy eventually stops working in advanced prostate cancer. Researchers will take tumor samples from 30 patients before and during treatment to study changes in immune cells and cancer markers. The goal is to find early signs of res…

This study looks at how screening for social needs (like food, housing, and transportation) and connecting Black breast and prostate cancer survivors with community health workers can improve their quality of life and well-being. Researchers are also testing anti-racism training …

This study follows 200 African American prostate cancer survivors and their partners to understand how daily stress, social support, and lifestyle choices like physical activity and diet affect each other. Participants wear an activity tracker and answer surveys on their smartpho…

This study looks at whether removing lymph nodes during prostate cancer surgery helps prevent the cancer from coming back in men with intermediate-risk prostate cancer. Currently, the procedure is standard but can cause side effects like swelling, blood clots, or nerve injury. Th…

This study collects blood and saliva samples from people with cancer and their relatives to build a DNA bank. Researchers hope to better understand how cancer runs in families. About 992 participants are expected to join. The samples will be stored and analyzed later for genetic …

This study looks at whether a protein in the blood called chromogranin A (CgA) can help predict if prostate cancer will come back after radiation therapy. Researchers will measure CgA levels in 118 men before, during, and after treatment. The goal is to see if changes in CgA are …

This study reviews the results of robotic prostate surgery in over 1,500 men with prostate cancer. Researchers are collecting data on patient characteristics and surgical outcomes, including survival and cancer recurrence. The goal is to understand how well the surgery works and …

This study is looking at how things like diet, physical activity, and other lifestyle habits might affect a man's risk of getting prostate cancer. Researchers are studying more than 2000 men who are at higher risk to find biological markers in the blood that could help predict ri…

This study aims to see how prostate tumors change on MRI scans shortly after a precise type of radiation therapy (SBRT). Researchers will compare these MRI changes with PSA levels in the blood. The study involves 28 men with localized prostate cancer and is designed to improve un…

This study follows nearly 2,000 men with newly diagnosed prostate cancer to see if certain genes increase the risk of the cancer spreading. Researchers will analyze genetic markers to better predict who might face more aggressive disease. The goal is to improve early detection of…

This study follows 2,500 prostate cancer survivors who had surgery at City of Hope. Researchers track their quality of life, side effects, and long-term health for years after treatment. The goal is to learn what survivors experience over time and find ways to improve their care.

This study looks at how two types of prostate cancer surgery affect breathing. Sixty men will be randomly assigned to either robot-assisted or open surgery. The main goal is to measure changes in peak expiratory flow (how fast you can blow air out) right after surgery and again a…

This study explores whether advanced MRI scans can detect early changes in prostate tumors and nearby healthy tissues during radiation therapy. By spotting these changes sooner, doctors might adjust treatment to improve effectiveness and reduce side effects. The study involves 38…

This study analyzes medical records and biopsy samples from 3,350 men diagnosed with localized prostate cancer between 1990 and 2006. The goal is to identify biological, pathological, and clinical markers that can predict how the disease will progress. By understanding these fact…

This study was designed to explore how the drug ruxolitinib affects immune cells inside prostate tumors. Researchers planned to give the drug to men with prostate cancer for 28 days before their scheduled surgery, then analyze tumor and blood samples. However, the study was withd…

This study collects tissue and blood samples from 156 people with advanced prostate, kidney, or bladder cancers. Researchers analyze these samples to find genetic markers that predict how well different treatments will work. Participants do not receive any experimental treatment …

This study looks at whether a special type of MRI, called RSI-MRI, can predict how well prostate cancer responds to radiation and hormone therapy. About 100 men with high-risk, localized prostate cancer will get this MRI before and during treatment. The goal is to see if the scan…

This study explores whether special PET scans (PSMA-PET) can better track how well treatment is working in men with metastatic hormone-sensitive prostate cancer. Twenty participants will receive standard care and undergo scans before and after 6 months of treatment. The goal is t…